

Resource Summary Report

Generated by [RRID](#) on Jul 31, 2026

RPMI-1788

RRID:CVCL_2710

Type: Cell Line

Proper Citation

JCRB Cat# IFO50037, RRID:CVCL_2710

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2710

Proper Citation: JCRB Cat# IFO50037, RRID:CVCL_2710

Description: Cell line RPMI-1788 is a Transformed cell line with a species of origin Homo sapiens (Human)

Sex: Male

Defining Citation: [PMID:62390](#), [PMID:305004](#), [PMID:2985879](#), [PMID:3159941](#), [PMID:3874327](#), [PMID:4366935](#), [PMID:6160588](#), [PMID:8139288](#), [PMID:9290701](#), [PMID:11173916](#), [PMID:16260726](#), [PMID:20889555](#), [PMID:29892436](#), [PMID:29959025](#)

Comments: Population: Caucasian., Part of: Human variation panel., Part of: Genetic Testing Reference Material (GeT-RM) samples.

Category: Transformed cell line

Organism: Homo sapiens (Human)

Name: RPMI-1788

Synonyms: RPMI 1788, RPMI1788, Roswell Park Memorial Institute 1788, GM02131, GM2131, GM02131A, GM17219

Cross References: BTO:BTO_0005255, CLO:CLO_0008867, CLO:CLO_0013924, CLO:CLO_0031846, CLO:CLO_0051022, CLDB:cl4169, CLDB:cl4170, CLDB:cl4171, ATCC:CCL-156, BioSample:SAMN00807500, BioSample:SAMN03471459, BioSample:SAMN03472770, CLS:300318, Coriell:GM02131, Coriell:GM17219, ECACC:85112106, FANTOM5_SSTAR:10427-106D4, GEO:GSM569533, GEO:GSM596283, GEO:GSM596643, GEO:GSM924821, IZSLER:BS CL 75, JCRB:IFO50037, JCRB:JCRB0035, KCLB:10156, RCB:RCB1878, TKG:TKG 0464, Wikidata:Q54951168

ID: CVCL_2710

Vendor: JCRB

Catalog Number: IFO50037

Record Creation Time: 20220427T221506+0000

Record Last Update: 20260726T000017+0000

Ratings and Alerts

No rating or validation information has been found for RPMI-1788.

Warning: Discontinued: KCLB; 10156

Population: Caucasian., Part of: Human variation panel., Part of: Genetic Testing Reference Material (GeT-RM) samples.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Jeong Y, et al. (2025) Dual targeting of EZH2 and PD-L1 in Burkitt's lymphoma enhances immune activation and induces apoptotic pathway. *Frontiers in immunology*, 16, 1578665.

Lernoux M, et al. (2020) Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells. *Clinical epigenetics*, 12(1), 69.